KYMR [NASD]
Kymera Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own1.20% Shs Outstand51.65M Perf Week15.43%
Market Cap990.58M Forward P/E- EPS next Y-3.25 Insider Trans147.21% Shs Float47.44M Perf Month38.23%
Income-123.80M PEG- EPS next Q-0.71 Inst Own85.98% Short Float10.37% Perf Quarter-51.20%
Sales63.80M P/S15.53 EPS this Y-70.00% Inst Trans6.24% Short Ratio6.44 Perf Half Y-68.25%
Book/sh8.30 P/B2.37 EPS next Y-12.50% ROA-22.10% Target Price63.08 Perf Year-58.31%
Cash/sh8.36 P/C2.35 EPS next 5Y-14.90% ROE-30.40% 52W Range13.15 - 69.12 Perf YTD-69.02%
Dividend- P/FCF- EPS past 5Y- ROI-21.80% 52W High-71.54% Beta-
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin- 52W Low49.58% ATR1.57
Employees143 Current Ratio4.90 Sales Q/Q-48.70% Oper. Margin- RSI (14)57.88 Volatility10.50% 9.43%
OptionableYes Debt/Eq0.00 EPS Q/Q-142.50% Profit Margin- Rel Volume1.10 Prev Close20.73
ShortableYes LT Debt/Eq0.00 EarningsMay 03 BMO Payout- Avg Volume763.39K Price19.67
Recom2.00 SMA2022.23% SMA50-5.83% SMA200-54.63% Volume830,983 Change-5.11%
Apr-28-22Initiated Credit Suisse Outperform $63
Mar-10-22Initiated JP Morgan Neutral $44
Feb-10-22Initiated Wells Fargo Overweight $62
Sep-30-21Initiated Stifel Buy $80
Sep-30-21Initiated B. Riley Securities Neutral $67
Sep-10-21Downgrade BofA Securities Buy → Neutral $65 → $80
May-21-21Initiated UBS Buy $80
Apr-14-21Initiated Berenberg Buy
Dec-04-20Initiated H.C. Wainwright Buy $85
Sep-15-20Initiated Morgan Stanley Equal-Weight $27
Sep-15-20Initiated Guggenheim Buy $42
Sep-15-20Initiated Cowen Outperform
Sep-15-20Initiated BofA Securities Neutral $35
Jun-18-22 10:35AM  
Jun-15-22 07:00AM  
Jun-01-22 08:42AM  
07:00AM  
06:15AM  
May-20-22 07:30AM  
May-10-22 08:26AM  
May-05-22 08:00AM  
May-04-22 09:31AM  
May-03-22 02:18PM  
08:15AM  
07:00AM  
Apr-19-22 08:00AM  
Apr-08-22 01:02PM  
Mar-02-22 07:00AM  
Feb-24-22 10:15AM  
07:00AM  
Feb-20-22 12:47AM  
Feb-17-22 05:15PM  
Feb-07-22 07:55AM  
Jan-25-22 08:00AM  
Jan-18-22 08:00AM  
Jan-12-22 12:42PM  
Jan-10-22 07:00AM  
Jan-04-22 08:00AM  
Dec-22-21 11:11AM  
Dec-16-21 07:00AM  
Dec-13-21 08:00AM  
Dec-06-21 08:00AM  
Nov-30-21 08:00AM  
Nov-17-21 08:00AM  
Nov-12-21 07:00AM  
Nov-10-21 08:25AM  
07:00AM  
Nov-08-21 07:35AM  
Nov-04-21 08:00AM  
Nov-03-21 11:26AM  
Nov-01-21 08:00AM  
Oct-27-21 07:00AM  
04:50AM  
Oct-25-21 10:16AM  
Oct-20-21 08:00AM  
Oct-13-21 07:00AM  
Sep-16-21 01:43PM  
Sep-02-21 08:00AM  
Aug-08-21 03:37AM  
Aug-06-21 07:00AM  
Jul-29-21 07:00AM  
Jul-28-21 03:45PM  
Jul-12-21 08:00AM  
Jul-06-21 04:00PM  
Jun-30-21 09:45PM  
Jun-29-21 09:34AM  
08:56AM  
Jun-28-21 04:36PM  
08:55AM  
06:00AM  
Jun-21-21 04:00PM  
11:20AM  
08:00AM  
Jun-09-21 08:00AM  
Jun-02-21 04:00PM  
May-26-21 09:00AM  
May-19-21 01:36AM  
May-10-21 09:00AM  
May-08-21 04:06AM  
May-06-21 07:00AM  
May-05-21 07:00AM  
May-04-21 07:00AM  
May-03-21 04:00PM  
08:00AM  
Apr-19-21 07:30AM  
Apr-10-21 08:30AM  
Apr-09-21 07:30AM  
Mar-16-21 04:01PM  
Mar-11-21 07:00AM  
Mar-02-21 07:00AM  
Feb-25-21 07:00AM  
Feb-04-21 07:00AM  
Feb-03-21 07:00AM  
Jan-12-21 07:00AM  
Jan-05-21 04:01PM  
Dec-19-20 07:24PM  
Dec-16-20 07:00AM  
Dec-07-20 10:00AM  
Nov-26-20 12:22AM  
Nov-23-20 08:00AM  
Nov-21-20 03:15AM  
Nov-11-20 08:00AM  
Nov-05-20 07:00AM  
Nov-04-20 10:01AM  
Oct-12-20 07:00AM  
04:19AM  
Oct-09-20 07:00AM  
Sep-14-20 07:00AM  
Sep-09-20 07:00AM  
Aug-27-20 07:00AM  
Aug-25-20 04:01PM  
Aug-20-20 08:36PM  
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/ILDirectorMay 27Buy14.7865,369966,3372,195,696May 31 07:50 PM
BVF PARTNERS L P/ILDirectorMay 26Buy14.21224,0573,183,9842,159,903May 31 07:50 PM
BVF PARTNERS L P/ILDirectorMay 20Buy14.0010,100141,3942,036,860May 24 08:09 PM
BVF PARTNERS L P/ILDirectorMay 06Buy19.25100,0001,925,5002,030,977May 09 07:20 PM
BVF PARTNERS L P/ILDirectorMay 05Buy19.60150,0002,939,8651,975,767May 09 07:20 PM
Gollob JaredChief Medical OfficerMay 04Option Exercise1.6920,00033,74057,257May 04 09:02 AM
Mainolfi NelloChief Executive OfficerMay 03Option Exercise2.0820,00041,600502,199May 03 07:27 PM
Jacobs Bruce N.Chief Financial OfficerMay 03Option Exercise2.0820,00041,60060,814May 03 07:26 PM
BVF PARTNERS L P/ILDirectorJan 31Buy40.7034,4081,400,4061,900,272Jan 31 07:44 PM
BVF PARTNERS L P/ILDirectorJan 27Buy38.3395,9013,676,0681,880,187Jan 31 07:44 PM
BVF PARTNERS L P/ILDirectorJan 24Buy37.76272,76710,300,6371,822,145Jan 26 07:43 PM
Mainolfi NelloChief Executive OfficerJan 14Option Exercise2.0810,00020,800482,199Jan 14 05:30 PM
Jacobs Bruce N.Chief Financial OfficerJan 14Option Exercise2.0810,00020,80027,514Jan 14 05:15 PM
Mainolfi NelloChief Executive OfficerJan 12Option Exercise2.088,61217,913480,811Jan 12 07:30 PM
Jacobs Bruce N.Chief Financial OfficerJan 12Option Exercise2.0815,00031,20032,514Jan 14 05:01 PM
Mainolfi NelloChief Executive OfficerJan 12Sale52.088,612448,551472,199Jan 12 07:30 PM
Jacobs Bruce N.Chief Financial OfficerJan 12Sale51.8515,000777,68417,514Jan 14 05:01 PM
Mainolfi NelloChief Executive OfficerJan 11Option Exercise2.0816,92335,200489,122Jan 12 07:30 PM
Mainolfi NelloChief Executive OfficerJan 11Sale54.0016,923913,795472,199Jan 12 07:30 PM
Mainolfi NelloChief Executive OfficerJan 10Option Exercise2.0822,46546,727494,664Jan 12 07:30 PM
Mainolfi NelloChief Executive OfficerJan 10Sale53.2622,4651,196,397472,199Jan 12 07:30 PM
Mainolfi NelloChief Executive OfficerDec 16Option Exercise2.088,00016,640472,199Dec 16 04:49 PM
Jacobs Bruce N.Chief Financial OfficerDec 03Option Exercise2.0810,00020,80027,514Dec 03 06:43 PM
Jacobs Bruce N.Chief Financial OfficerDec 03Sale53.5610,000535,63717,514Dec 03 06:43 PM
Jacobs Bruce N.Chief Financial OfficerNov 23Option Exercise2.0810,00020,80017,256Nov 23 04:59 PM
Gollob JaredChief Medical OfficerNov 02Option Exercise2.0814,99631,19239,653Nov 02 06:45 PM
Gollob JaredChief Medical OfficerNov 02Sale63.2214,996948,06324,657Nov 02 06:45 PM
Gollob JaredChief Medical OfficerNov 01Option Exercise1.4524,60735,78367,154Nov 02 06:45 PM
Gollob JaredChief Medical OfficerNov 01Sale61.7842,4972,625,59524,657Nov 02 06:45 PM
Mainolfi NelloChief Executive OfficerOct 11Option Exercise2.086,45613,428470,655Oct 12 04:30 PM
Mainolfi NelloChief Executive OfficerOct 11Sale53.686,456346,590464,199Oct 12 04:30 PM
Mainolfi NelloChief Executive OfficerOct 08Option Exercise2.0841,54486,412505,743Oct 12 04:30 PM
Mainolfi NelloChief Executive OfficerOct 08Sale56.7641,5442,357,946464,199Oct 12 04:30 PM
Jacobs Bruce N.Chief Financial OfficerSep 03Sale60.1210,000601,1807,256Sep 03 05:57 PM
Chesworth RichardChief Scientific OfficerAug 27Option Exercise20.0033,779675,58033,779Aug 27 04:55 PM
Chesworth RichardChief Scientific OfficerAug 27Sale60.1233,7792,030,8640Aug 27 04:55 PM
Mainolfi NelloChief Executive OfficerAug 19Option Exercise2.0812,00024,960464,199Aug 19 04:30 PM
Chesworth RichardChief Scientific OfficerAug 17Option Exercise20.0054,0001,080,00054,000Aug 19 04:30 PM
Chesworth RichardChief Scientific OfficerAug 17Sale50.3754,0002,720,1820Aug 19 04:30 PM
Booth BruceDirectorAug 11Sale61.00242,13314,770,1130Aug 12 10:43 AM
ATLAS VENTURE ASSOCIATES X, L.10% OwnerAug 11Sale61.00242,13314,770,1130Aug 12 10:42 AM
Mainolfi NelloChief Executive OfficerAug 04Option Exercise2.081,0372,157453,236Aug 05 04:14 PM
Mainolfi NelloChief Executive OfficerAug 04Sale60.031,03762,253452,199Aug 05 04:14 PM
Mainolfi NelloChief Executive OfficerAug 03Option Exercise2.085,66911,792457,868Aug 05 04:14 PM
Mainolfi NelloChief Executive OfficerAug 03Sale60.075,669340,533452,199Aug 05 04:14 PM
Mainolfi NelloChief Executive OfficerAug 02Option Exercise2.0823,45648,788475,655Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerAug 02Sale60.3023,4561,414,404452,199Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerJul 30Option Exercise2.086,27913,060458,478Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerJul 30Sale60.076,279377,167452,199Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerJul 29Option Exercise2.086801,414452,879Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerJul 29Sale60.0068040,800452,199Aug 02 05:53 PM
Mainolfi NelloChief Executive OfficerJul 28Option Exercise2.083,8648,037456,063Jul 28 04:57 PM
Mainolfi NelloChief Executive OfficerJul 28Sale60.153,864232,410452,199Jul 28 04:57 PM
Mainolfi NelloChief Executive OfficerJul 26Option Exercise2.089,01518,751461,214Jul 28 04:57 PM
Mainolfi NelloChief Executive OfficerJul 26Sale60.159,015542,237452,199Jul 28 04:57 PM
Mainolfi NelloChief Executive OfficerJul 08Option Exercise2.0848,00099,840500,199Jul 09 04:30 PM
Mainolfi NelloChief Executive OfficerJul 08Sale49.7048,0002,385,628452,199Jul 09 04:30 PM
BVF PARTNERS L P/ILDirectorJul 01Buy47.00544,16625,575,8021,664,104Jul 06 06:40 PM